A practical reference on AOD-9604: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-05-15 and is reviewed periodically as new material appears.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide fragment | Not a full hormone |
| Molecular target | Proposed adipose tissue lipolysis | Receptor details uncertain |
| Typical research dose | Not established for clinical use | Doses vary across studies |
| Stability in solution | Limited; store cold | Avoid repeated freeze-thaw |
| Regulatory status | Not approved as a drug | Varies by country |
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Voglibose (INN and USAN, trade name Voglib, marketed by Mascot Health Series) is an alpha-glucosidase inhibitor used for lowering postprandial blood glucose levels in people with diabetes mellitus. Voglibose is a research product of Takeda Pharmaceutical Company, Japan's largest pharmaceutical company. Voglibose was discovered in 1981, and was first launched in Japan in 1994, under the trade name BASEN, to improve postprandial hyperglycemia in diabetes mellitus. Postprandial hyperglycemia (PPHG) is primarily due to first phase insulin secretion. Alpha glucosidase inhibitors delay glucose absorption at the intestine level and thereby prevent sudden surge of glucose after a meal. There are three major drugs which belong to this class, acarbose, miglitol and voglibose, of which voglibose is the newest.
== Evolution == By virtue of its antibacterial properties, it has been speculated that sv-LAAOs are in part responsible for the maintenance and stabilization of both the venom and venom gland in snake species.
[M(H2O)n] + L ⇌ [M(H2O)n−1L] + H2O However, since water is in vast excess, the concentration of water is usually assumed to be constant and is omitted from equilibrium constant expressions. Often, the metal and the ligand are in competition for protons. For the equilibrium
Sources: en.wikipedia.org
Pennington was born on October 8, 1872, in Nashville, Tennessee, to Henry and Sarah Malony Pennington. Shortly after her birth, her parents moved to Philadelphia to be closer to her mother's Quaker relatives. She became interested in chemistry at the age of 12 after reading a library book on medicinal chemistry. She walked to the University of Pennsylvania and asked a professor for help with the terminology she did not understand. She was told to come back when she was older. She entered the University of Pennsylvania in 1890 and completed the requirements for a B.S. degree in chemistry with minors in botany and zoology in 1892. However, since the University of Pennsylvania did not grant degrees to women at this time, she was given a certificate of proficiency instead of a degree. Pennington received her Ph.D. from the University of Pennsylvania in 1895. Her thesis was entitled "Derivatives of Columbium and Tantalum." From 1895 to 1896, she was a university fellow in botany at the University of Pennsylvania. She was a fellow in physiological chemistry at Yale University from 1897 to 1899, and conducted research with Lafayette Mendel and Russell Henry Chittenden.
The existence of graphene was first theorized in 1947 by Philip R. Wallace during his research on graphite's electronic properties, while the term graphene was first defined by Hanns-Peter Boehm in 1987, when he and coworkers isolated single sheets from graphite. In 2004, the material was isolated and characterized by Andre Geim and Konstantin Novoselov at the University of Manchester using a piece of graphite and adhesive tape. In 2010, Geim and Novoselov were awarded the Nobel Prize in Physics for their "groundbreaking experiments regarding the two-dimensional material graphene". While small amounts of graphene are easy to produce using the method by which it was originally isolated, attempts to scale and automate the manufacturing process for mass production have had limited success out of concern for cost-effectiveness and quality control. The global graphene market was $9 million in 2012, with most of the demand from research and development in semiconductors, electronics, electric batteries, and composites. In 2022, the graphene market reached an estimated global annual revenue of $380 million. The IUPAC (International Union of Pure and Applied Chemistry) advises using the term "graphite" for the three-dimensional material and reserving "graphene" for discussions about the properties or reactions of single-atom layers. A narrower definition, of "isolated or free-standing graphene", requires that the layer be sufficiently isolated from its environment, but would include layers suspended or transferred to silicon dioxide or silicon carbide.
== Description == Strobilanthes alternata is a herbaceous plant that reaches approximately 30 cm (12 in) in length. The stems of the plant are prostrate and purplish, especially at the nodes. The leaves, which are covered in fine hairs, are arranged oppositely on the stem with one leaf noticeably larger than its counterpart. The leaf blades are dark green on the top face and are lighter green or purplish on the lower face. Commonly known as the Cemetery plant, Purple waffle plant, or Murikooti, it is referred to in Ayurvedic medicine as Vranaropani, which translates to "wound healer". In Kerala, India, the local name for this herb is Muriyan pacha, a name related to belief in its wound-healing properties. This plant is native to the tropical regions of the globe especially tropical Malaysia and South East Asia. This natural herb grows in plenty across India, China, Indonesia, and Japan
Sources: en.wikipedia.org
2013 The pan-tissue Epigenetic clock is a molecular biomarker by Steve Horvath that facilitates the measurement of the age of all human tissues based on cytosine methylation. 2013 The scientific journal Cell published the article "The Hallmarks of Aging", that was translated to several languages and determined the directions of many studies. 2013 A record for the duration of life among males. Japanese Jiroemon Kimura lived 116 years and 54 days (that is 167 days longer than the previous record). 2013 It was discovered that brain-specific overexpression of Sirtuin 1 (SIRT1) is also capable to extend lifespan and delay aging in mice. 2013 Google and other investors created the company Calico to combat aging and related diseases. Investors provided Calico with more than a billion dollars of funding. Arthur Levinson became CEO of the company and one of its investors. 2014 First evidence that pharmacological activation of SIRT1 extends lifespan in mice and improves their health. 2014 Establishment of the Dog Aging Project at the University of Washington, a decade-long study of aging in dogs which includes clinical trials of rapamycin in some of them to test its effects on lifespan, with the project's ultimate goal being to translate the results into further understanding aging in humans and ways to target it. 2010s second half The emergence of official discussions about the possibility of recognizing aging as a disease.
Pollard MR, Anderson L, Fan C, Hawkins DJ, Davies HM (1991). "A specific acyl-ACP thioesterase implicated in medium-chain fatty acid production in immature cotyledons of Umbellularia californica". Arch. Biochem. Biophys. 284 (2): 306–12. doi:10.1016/0003-9861(91)90300-8. PMID 1989513. Davies HM, Anderson L, Fan C, Hawkins DJ (1991). "Developmental induction, purification, and further characterization of 12:0-ACP thioesterase from immature cotyledons of Umbellularia californica". Arch. Biochem. Biophys. 290 (1): 37–45. doi:10.1016/0003-9861(91)90588-A. PMID 1898097.
== Coaching team == Zverev has been coached by his parents since he was very young. His mother was initially his primary coach before his father took over at some point. Zverev made the decision to hire former world No. 1 Juan Carlos Ferrero at the Washington Open in the summer of 2017. He fired Ferrero following the 2018 Australian Open after Ferrero criticized the rest of Zverev's coaching team. Ivan Lendl, another former world No. 1, joined Zverev's team in August 2018. They split up in July 2019 due to disappointing results and personal differences. Zverev has stated that Lendl was more interested in his dog or his golf game than in professional coaching. In 2020, Zverev started to work with former World Number 3 and 2013 French Open Finalist David Ferrer. They announced their split in January 2021. Zverev's coaching team also includes physio Hugo Gravil. Fitness trainer Jez Green, who previously worked with Andy Murray, also worked with Zverev beginning 2013. Green departed Zverev's team in 2021 after working with him for around seven years.
==== All-Russian Cossack Society ==== The All-Russian Cossack Society (Russian: Всероссийское казачье общество) is responsible for the coordination of the activities of all 11 registered Cossack hosts, particularly in the spheres of patriotic education and the continuity of historical Cossack customs and traditions. Both registered and non-registered Cossack organizations can be part of the society. On 4 November 2019, Russian President Vladimir Putin appointed Kuban Vice Governor and Kuban Cossack Host Ataman Nikolai Doluda as Ataman of the All-Russia Cossack Society. Cossack General Doluda was appointed two years after the atamans and the Cossacks created it in October 2017. The idea was first proposed in 1994. On 27 November 2018, delegates of the Constitutive Assembly voted for the establishment of the society and adopted its official statute. Doluda was then nominated for head of the society, in which he was backed by the Presidential Council on Cossack Affairs.
Sources: en.wikipedia.org
It is proposed to promote lipolysis in fat tissue, the breakdown of stored fat into fatty acids and glycerol. The detailed receptor and signaling mechanisms are not fully established.
Because it is a fragment rather than full growth hormone, it is generally described as lacking growth-promoting effects. Some studies suggest it may influence fat metabolism without the same systemic growth effects, though evidence is limited.
Human trials have measured body weight, fat mass, lean mass, lipid levels, and adverse events. Most have been small or short-term, so conclusions about long-term outcomes are limited.
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.